Frank Sciurba, M.D., FCCP

Dr. Frank Sciurba Bio
Dr. Frank Sciurba, M.D. is a Tenured Professor at the University of Pittsburgh School of Medicine. He is the director of the Emphysema COPD Research Center and the Director of the Clinical Pulmonary physiology laboratories and pulmonary rehabilitation program. He earned his B.S. degree in Biochemistry from the University of Illinois and attended medical school at the University of Chicago Pritzker School of Medicine. Dr. Sciurba completed his residency and fellowship in Pulmonary and Critical Care Medicine at the University of Pittsburgh Medical Center.
Dr. Sciurba’s research has been inspired by real clinical problems facing his patients. He has authored over 400 peer reviewed publications with a particular emphasis on lung physiology and COPD. Dr. Sciurba is fully supported on grants from the National Institutes of Health, foundations, and industry. He is also a member of the Western PA Regional American Lung Association Board.
Financial relationships
-
Attribution:SelfType of financial relationship:ConsultantIneligible company:Sanofi/RegeneronTopic:DupilimabDate added:02/25/2026Date updated:02/25/2026
-
Attribution:SelfType of financial relationship:ConsultantIneligible company:AstraZenecaTopic:TozorakimabDate added:02/25/2026Date updated:02/25/2026
-
Attribution:SelfType of financial relationship:ConsultantIneligible company:GlaxoSmithKlineTopic:MepolizumabDate added:02/25/2026Date updated:02/25/2026
-
Attribution:SelfType of financial relationship:ConsultantIneligible company:GenentechTopic:AstegolimabDate added:02/25/2026Date updated:02/25/2026
-
Attribution:SelfType of financial relationship:ResearcherIneligible company:Sanofi/RegeneronTopic:DupilimabDate added:02/25/2026Date updated:02/25/2026
-
Attribution:SelfType of financial relationship:ResearcherIneligible company:AstraZenecaTopic:TozorakimabDate added:02/25/2026Date updated:02/25/2026
-
Attribution:SelfType of financial relationship:ResearcherIneligible company:Verona PharmaTopic:EnsifentrineDate added:02/25/2026Date updated:02/25/2026
-
Attribution:SelfType of financial relationship:ResearcherIneligible company:NuvairaTopic:Targeted lung denervationDate added:02/25/2026Date updated:02/25/2026
-
Attribution:SelfType of financial relationship:ResearcherIneligible company:Gala TherapeuticsTopic:Bronchial rheoplastyDate added:02/25/2026Date updated:02/25/2026
-
Attribution:SelfType of financial relationship:ResearcherIneligible company:PulmonxTopic:Zephyr valvesDate added:02/25/2026Date updated:02/25/2026

Facebook
X
LinkedIn
Forward